Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Consistent long-term performance driving confidence for the future Strong performance in Q2 driven by the momentum of key growth drivers including Cosentyx®, EntrestoⓇ, ZolgensmaⓇ and Oncology portfolio Pipeline of novel medicines continues to progress including positive readouts in diseases with high unmet need with iptacopan, ZolgensmaⓇ and 177 Lu-PSMA-617 Reconfirming FY 2021 guidance and our commitment to drive long-term accretive growth 40 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation